In its updated clinical guideline on the management of MS in primary and secondary care, NICE advised that patients should not be offered the cannabis-derived oromucosal spray Sativex to treat spasticity or the oral treatment fampridine (Fampyra) to improve walking disability. NICE judged that neither option was cost-effective.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
Register or Subscribe to MIMSGPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.
MIMS bulletinsNews and updates straight to your inbox.
Prescribing Update: Fortnightly news bulletin
Alert: Urgent prescribing updates
Spotlight: Disease-themed monthly round-up
Read the latest issue online exclusively on MIMS Learning.
Handy calculators and conversions for primary care.